{"id":"CU24363","slug":"safer-iboga-analogs-for--CU24363","source":{"id":"CU24363","dataset":"techtransfer","title":"Safer iboga analogs for treating psychiatric and neurological disorders","description_":"<p>This technology describes two sets of iboga analogs designed to reduce side effects and improve bioavailability relative to ibogaine, with potential applications in substance use disorders (SUDs), mood and anxiety disorders including PTSD, and other neurological conditions.</p>\r\r<h2>Unmet Need: Safe and effective therapies for SUD, PTSD, and neurological disorders</h2>\r\r<p>Psychiatric and neurological disorders involving altered neuroplasticity, including substance use disorders (SUDs) and PTSD, remain challenging to treat with existing behavioral and pharmacologic approaches. Current therapies often show variable efficacy, require long-term adherence, and may not fully address the co-occurring conditions such as anxiety or depression. Psychoactive compounds like ibogaine have shown therapeutic potential, but clinical translation has been limited by regulatory restrictions and safety concerns, including hallucinogenic effects and cardiotoxicity. Therefore, there is a need for safer and more clinically viable approaches to address substance use and trauma-related neuropsychiatric disorders. </p>\r\r<h2>The Technology: Safer iboga analogs to induce therapeutic neuroplasticity</h2>\r\r<p>This technology describes modified iboga analogs designed to improve safety while retaining anti-addictive and neuroplasticity-promoting properties, making them potential therapeutics for conditions involving altered neuroplasticity. Compared to ibogaine, a naturally derived psychoactive alkaloid from the <i>Tabernanthe iboga </i> plant, these analogs reduce hallucinogenic and toxic side effects while maintaining similar pharmacological activity at relevant molecular targets. Furthermore, the “tropa-iboga” class of analogs exhibits increased oral bioavailability, which may support more practical administration and facilitate clinical translation for psychiatric and neurological disorders.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Treatment of substance use disorders</li>\r<li>Therapeutic for psychiatric conditions including depression, anxiety, mood disorders, and PTSD</li>\r<li>Management of neurological conditions, including traumatic brain injury (TBI), multiple sclerosis (MS), and Parkinson’s disease</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Similar pharmacological properties to ibogaine </li>\r<li>Reduced risk of hallucinogenic and toxic side effects</li>\r<li>Improved safety profile</li>\r<li>Improved oral bioavailability</li>\r<li>Broad therapeutic potential for different neuroplasticity-related disorders</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://www.chem.columbia.edu/content/dalibor-sames\">Dalibor Sames, Ph.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending</p>\r\r<h2>Related Publications:</h2>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU24363, CU25444</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Jerry Kokoshka</a></p></li>\r</ul>\r","tags":["Alkaloid","Bioavailability","Cardiotoxicity","Comorbidity","Ibogaine","Multiple sclerosis","Neuroplasticity","Post-traumatic stress disorder","Psychoactive drug","Tabernanthe iboga","Traumatic brain injury"],"file_number":"CU24363","collections":[],"meta_description":"Ibogaine-like compounds that boost therapeutic neuroplasticity with less toxicity and better oral bioavailability.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":4.0},\"weighted_score\":3.55,\"risks\":[\"Patent protection pending may delay commercialization\",\"Safety/efficacy in humans unproven; need extensive preclinical/clinical validation\",\"Regulatory and safety concerns with ibogaine-class derivatives\",\"Complex synthesis or manufacturing challenges could affect scalability\",\"Market competition from other neuropsychiatric agents and substance-use disorder therapies\"],\"one_sentence_take\":\"Promising novel iboga analogs with safer profile and oral bioavailability, but needs solid patent protection and rigorous clinical validation to realize scalable, timely impact.\"}","inventors":["Dalibor Sames","David Lankri","Vaclav Havel"],"manager":"Jerry Kokoshka","depts":["Chemistry"],"divs":["Faculty of the Arts & Sciences"],"date_released":"2026-06-05"},"highlight":{},"matched_queries":null,"score":0.0}